Abbreviations: AZ, AstraZeneca; CMV, cytomegalovirus; CRC, colorectal cancer; G6Pase, glucose 6-phosphatase; hMPV, human metapneumovirus; IL12, interleukin 12; IL23, interleukin 23; IL36γ, interleukin 36 gamma; MUT, methylmalonyl-CoA mutase; NSCLC, non-small cell lung cancer; PAH, phenylalanine hydroxylase; PCCA/PCCB, propionyl-CoA carboxylase subunit A/B; PCV, personalized cancer vaccine; PIV3, human parainfluenza 3; RSV, respiratory syncytial virus; VEGF-A, vascular endothelial growth factor A.
Our development pipeline illustrates the progress we’re making on Moderna’s clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new vaccines and therapeutics that may have the potential to treat rare diseases like Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA), and prevent disease such as Cytomegalovirus (CMV), Zika and cancers. View the progress of our mRNA clinical pipeline below.
Modality
Program Indication
ID #
Preclinical development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
Core modalities
Adults
COVID-19 vaccine
mRNA-1273
Worldwide
COVID-19 vaccine
mRNA-1273.351
Beta variant
Worldwide
COVID-19 vaccine
mRNA-1273.617
Delta variant
Worldwide
COVID-19 vaccine
mRNA-1273.211
Beta variant + wild-type
Worldwide
COVID-19 vaccine
mRNA-1273.213
Beta+Delta variant
Worldwide
COVID-19 vaccine
mRNA-1273.529
Omicron variant
Worldwide
COVID-19 vaccine
mRNA-1283
Next generation (2-5 ºC)
Worldwide
Flu vaccine
mRNA-1010
Phase 3 prep
Worldwide
Flu vaccine
mRNA-1011
Worldwide
Flu vaccine
mRNA-1012
Worldwide
Flu vaccine
mRNA-1020
Worldwide
Flu vaccine
mRNA-1030
Worldwide
COVID + Flu vaccine
mRNA-1073
mRNA-1273
mRNA-1010
mRNA-1010
Worldwide
Respiratory syncytial virus (RSV) vaccine
mRNA-1345
Phase 2/3
Worldwide
Adolescents & Pediatrics
COVID-19 (adolescents)
mRNA-1273
TeenCOVE
Worldwide
COVID-19 vaccine (pediatrics)
mRNA-1273
KidCOVE
Worldwide
Pediatric RSV vaccine
mRNA-1345
Phase 1b
Worldwide
Pediatric hMPV+PIV3 vaccine
mRNA-1653
Worldwide
Pediatric RSV + hMPV vaccine
mRNA-1365
Worldwide
Latent Vaccines
CMV vaccine
mRNA-1647
Worldwide
Epstein-Barr virus (EBV) vaccine
mRNA-1189
Worldwide
EBV therapeutic vaccine
mRNA-1195
Worldwide
Prophylactic Vaccines
HIV vaccine
mRNA-1644
Open IND
Worldwide
IAVI/others funded
HIV vaccine
mRNA-1574
Worldwide
IAVI/BMGF/NIAID and others funded
Other Vaccines
Zika vaccine
mRNA-1893
Worldwide
BARDA funded
Nipah vaccine
mRNA-1215
Worldwide
NIH funded
Exploratory modalities
Systemic Secreted & Cell Surface Therapeutics
IL-2
Autoimmune disorders
mRNA-6231
Worldwide
Relaxin
mRNA-0184
Worldwide
PD-L1
Autoimmune hepatitis
mRNA-6981
Worldwide
Cancer Vaccines
Personalized cancer vaccine (PCV)
mRNA-4157
50-50 global profit sharing with Merck
KRAS vaccine
mRNA-5671
50-50 global profit sharing with Merck
Intratumoral Immuno-Oncology
OX40L/IL-23/IL-36γ (Triplet)
Solid tumors/lymphoma
mRNA-2752
Worldwide
IL-12
Solid tumors
MEDI1191
50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales
Localized Regenerative Therapeutics
VEGF-A
Myocardial ischemia
AZD8601
AZ to pay milestones and royalties
Systemic Intracellular Therapeutics
PCCA/PCCB
Propionic acidemia (PA)
mRNA-3927
Worldwide
MUT
Methylmalonic acidemia (MMA)
mRNA-3705
Worldwide
G6Pase
Glycogen Storage Disease
Type 1a (GSD1a)
mRNA-3745
Open IND
Worldwide
PAH
Phenylketonuria (PKU)
mRNA-3283
Worldwide
Crigler-Najjar Syndrome Type 1 (CN-1)
mRNA-3351
Provided to ILCM,
Institute for Life
Changing Medicines
free of charge
Inhaled Pulmonary Therapeutics
Cystic Fibrosis (CF)
VXc0522
Vertex to pay milestones and royalties